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EDITORIAL

Hypertension in CKD: Sodium Still at the Nexus

T

he co-editors of this issue of Advances in Chronic Kidney
Disease, Drs John Sperati and Adam Whaley-Connell,
have succeeded in bringing together a series of articles
that comprehensively, yet concisely, describe that which
is most contemporarily important in the area of secondary
hypertension. Notably, this issue was purposefully placed
to follow the most recent issue of Advances in Chronic Kidney Disease co-edited by Cohen, Goldman, and Sim and
which focused on hypertension in general. Aldosterone,
the intrarenal renin-angiotensin system, pharmacologically and inadvertently induced aggravation of high blood
pressure, catecholaminergic excess, insulin resistance and
diabetes, sodium and extracellular volume expansion, and
cardiotonic steroids, are all discussed within the context of
secondary hypertension. However, many of the same factors are part and parcel of the secondary hypertension,
that is, CKD (Fig 1).
Although, internists and family physicians frequently
search for a cause of secondary hypertension, in general,
the cause is identiﬁed in no more than 5% to 10% of patients who are evaluated because this is the proportion
of cases of secondary hypertension disclosed in specialty
hypertension clinics. If parenchymal disease of the kidney,
excepting congenital and acquired renal artery stenotic
disorders, is considered a cause of secondary hypertension, then hypertension in association with CKD is clearly
the most prevalent cause of secondary hypertension. This
fact is easily determined simply by using an age-based
approach to the etiologies of secondary hypertension.1
The inextricable linking of hypertension to kidney disease
was established decades ago, and our current International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation and not-too-distant future International Classiﬁcation
of Diseases, Tenth Revision, Clinical Modiﬁcation diagnostic
coding of so-called “hypertensive nephrosclersosis” combines these 2 entities into, respectively, 403.xx and I12.x.2
The latter code will prevail irrespective of whether hypertension has actually stemmed from CKD or vice versa.
This will be particularly nettlesome in hypertensive
CKD of African-Americans who may actually have an
APOL1 genopathy—glomerulopathy from 2 high-risk
APOL1 alleles with secondary hypertension.3 In the initial
characterization of APOL1, the frequency of the APOL1
G1 allele in Yorubans (largest of the 3 major Nigerian

tribes) was 38% and for the G2 allele 8%, thus illustrating
the riskiness for the misdiagnosis of hypertensive CKD in
African-Americans who may actually have a form of
glomerular disease characterized by focal and segmental
glomerulosclerosis.
Correspondingly, nephrologists must have high-level
appreciation of what drives hypertension in CKD.
Furthermore, steps to abrogate the pathogenetic steps
and sequences that are involved in the pathobiology of
high blood pressure in CKD must be judiciously applied,
distributed, and balanced. A brief list of abnormalities
that are assailable by our current therapeutic armamentarium includes an expanded extracellular ﬂuid volume,
an elevated sympathetic nervous system, metabolic
acidosis, and insulin resistance syndromes (Fig 1). The
interplay of the latter 3 converges on the ﬁrst, the manifestation of sodium, which resides at the nexus of hypertension in CKD.
Despite the compensatory increase of ﬁltration fraction
during the evolution of CKD, sodium is retained and
the extracellular ﬂuid volume correspondingly increases.
Sodium restriction is the cornerstone of therapy, and it
must be instituted vigorously and monitored by a kidney
nutritionist and the physician. A simple way to do this is
to monitor and surveil sodium intake. Twenty-four-hour
urine sodium collections have demonstrated that the
adult population of the United States favors a high sodium intake, on the order of 160 mmol daily for black
and white individuals,4 and even when an individual
cannot obtain a monitored 24-hour specimen, estimation
of the daily sodium excretion may be extrapolated from
a “casual” specimen.4
Our penchant for salt has remained disturbingly unchanged from the period of 1957 to 2010 per analysis of
38 studies conducted during that interval,5 despite the remonstrations of proponents of US dietary sodium guidelines, such as the Institute of Medicine and American
Heart Association.6 The 2013 Institute of Medicine report
contradicted its former recommendation by stating that
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Figure 1. Cause and effect diagram of forces that increase total body sodium content. Primary sodium accrual forces (solid
line boxes and arrows) that increase total body sodium are opposed by forces that reduce sodium accumulation (dashed line
boxes and lines). Therapeutic maneuvers (dashed arrows) that interdict primary sodium accrual forces are also depicted
(dashed arrows). Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AKI,
acute kidney injury; ARA, aldosterone receptor antagonist; CTD, chlorthalidone; DM, diabetes mellitus; DRI, direct renin inhibitor; F 1 V, fruits and vegetables diet; IR, insulin resistance; K, potassium; Na, sodium; Na-HCO3, sodium bicarbonate; RAS,
renin-angiotensin system; SNS, sympathetic nervous system; U(Na, K), urine sodium and potassium concentrations.

there was no safe upper limit of sodium intake and that
sodium intake below 2300 mg (100 mmol) was associated
with an increase in mortality. These data were for the general population and not for CKD patients where excessive
sodium intake is clearly pathogenic and worsens hypertension. Lastly, spot urine sodium-to-potassium ratios
may be more predictive of blood pressure lowering than
either sodium intake or potassium intake alone. Lower ratios in adult hypertensive patients may reﬂect relative
suppression of the renin-angiotensin-aldosterone system
by potassium,7 with ratios of 0.53 to 1.68 proving salutary.
Potassium intake was more important than sodium restriction, overall.
Diuretic therapy after dietary sodium restriction can be
improved. Recognition that loop agents are threshold
drugs that must be used twice daily or more, in most instances, is a start. After the “braking phenomenon” begins, be it from augmented proximal tubule of sodium
through angiotensin II and/or stimulation of adrenergic
receptors, post-loop of Henle cellular hypertrophy, or
compensatory sodium reabsorption downstream, an
additional diuretic may be required. Recently, Agarwal
and colleagues8 recapitulated the additive natriuretic
and blood pressure-lowering effect of distal convoluted
blockade with the thiazide-like diuretic, chlorthalidone,
in a pilot study of advanced CKD. Previously, Ellison
and colleagues had elegantly shown in an animal model
that the sympathetic nervous system increased the phosphorylated form of the sodium chloride cotransporter

(pNCC1) at the distal convoluted tubule,9 thereby connecting the known ampliﬁcation of high blood pressure
in CKD by the sympathetic nervous system (SNS) to
more than simply enhanced vasoconstriction.
In primarily stage 4 CKD patients with a mean estimated glomerular ﬁltration rate of 28 mL/min/1.73 m2,
chlorthalidone, in a forced-titration dosing strategy of 25
to 100 mg daily, impressively reduced the systolic blood
pressure by nearly 10 mm Hg, following 12 weeks of
chlorthalidone treatment.8 Hypokalemia occurred in a
signiﬁcant number of subjects, both establishing the utility
of this approach and its potential hazard. Using wholebody plethysmography, the nonedematous participants
were found to have lost an average of 2.2 kg, underscoring
the volume-expanded nature of the CKD patient with hypertension and its surreptitious nature. If further diuresis
above and beyond that obtainable through chlorthalidone
is desired, blockade of more distal sodium reabsorption
by the epithelial sodium channel with amiloride or triamterene or of the collecting duct by spironolactone or epleronone may be attempted. Amiloride also reduces, to a
minor extent, sodium reabsorption in the collecting duct
and nearly completely abolishes angiotensin II-mediated
hydrogen ion secretion by the proximal tubules by blocking the apical sodium-hydrogen exchanger-3. Tempering
of potassium loss by any of these agents is accompanied
by a reinforcement of saliuresis.
At least in chronic hemodialysis patients, the “hidden”
sodium by 23Na magnetic resonance imaging is resident
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in the skin and muscle.10 Greater amounts of tissue sodium content in dialysis patients older than 60 years
correlated with lesser amounts of vascular endothelial
growth factor-C, in comparison with age-matched
controls. Before this human observation, the laboratory
of Titze had re-established the primacy of sodium in
the pathogenesis of hypertension in CKD in an animal
model,11 whereby a high-salt diet led to cutaneous hypertonic sodium accumulation and interstitial volume
expansion and higher blood pressure. This maladaptive
response is attenuated in part by vascular endothelial
growth factor-C-induced recruitment of macrophages
and construction of a lymphangiocapillary network
that buffers excessive interstitial sodium and water,
and this critical factor is depleted in CKD and with
aging.
The SNS also invigorates the systemic and intrarenal
renin-angiotensin systems, and therapeutic suppression
of the SNS should be a goal in the treatment of hypertension in CKD. a- and b-blocker treatments are often applied
in this circumstance. However, once-daily guanfacine
may be favorable to multiply dosed clonidine with its
longer plasma half-time, superior systolic blood pressure
reduction, and lesser tendency to rebound hypertension
postdrug withdrawal.12 Third-generation b-blocker therapy (eg, labetalol, carvedilol, nebivolol) like their forerunners depresses the peripheral effects of the SNS. These
newer agents may provide greater vasodilation by
increasing vasodilator nitric oxide production, which is
deﬁcient in insulin-resistant states or frank diabetes. Interestingly, nebivolol offers the additional advantage of
improved sexual activity compared with metoprolol.13
Note that combined a- and b-blockade for the treatment
of hypertension has not been shown superior to the antihypertensive efﬁcacy of either ﬁrst- or second-generation
b blockers.14
In addition, the activity of the SNS is augmented by sustained hyperglycemia, rendering the states of insulin resistance or frank diabetes susceptible to blood pressure
elevation by 1 or more of the aforementioned mechanisms.15,16 An intriguing and plausible hypothesis that
originates from this observation would be whether
glucosuria as treatment of hyperglycemia would
moderate SNS activity and provide additive effects on
blood pressure control. The advent of sodium glucose
cotransporter-2 inhibition by the “gliﬂozin” class of drugs
may provide insight into the verity of this postulate.17 To
date, modest blood pressure reductions have been demonstrated with canagliﬂozin, and these were achieved
concomitant with weight reduction, partially mediated
by the sodium reabsorptive defect imposed by SGLT2
inhibition at proximal tubule segments 1 and 2. Coupled
with metformin therapy, SGLT2 inhibition may provide
a potent “1-2 punch” for mitigation of hyperglycemia.
The SNS is often increased during sleep in diabetes, and
ambulatory blood pressure monitoring that demonstrates
the entity of isolated nocturnal hypertension calls for
institution of antihypertensive agents at night.18 In addition, any further nocturnal (and then daytime) blood
pressure challenges imposed by sleep apnea, obstructive
or not, must be successfully contended with. Lastly,
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vagal impairment with autonomic neuropathy may tip
the balance of the autonomic nervous system toward the
SNS.19
Sympathetic nerve activity is increased by pH
lowering, either by metabolic or respiratory acidosis.
Rostral ventrolateral medullary sympathoexcitatory
neuronal output is stimulated equally by either form of
acidosis at equal decrements of pH. However, at preganglionic sympathetic neurons, respiratory acidosis imparts a profoundly greater degree of excitation at equal
levels of pH lowering.20 Furthermore, acidemia in CKD
may aggravate sodium retention by stimulating the
SNS, worsen insulin resistance,21 intensify vasoconstriction through the SNS, and raise blood pressure.
Moreover, there is preserved sodium bicarbonate cotransporter (NBCe1) activity in the proximal tubule
during insulin resistance per se in the metabolic syndrome, the consequence of which is a promotion of
salt-sensitive hypertension.22 The abolition of sodium reabsorption at the NBCe1 locus by a carbonic anhydrase
inhibitor could be coupled to concomitant administration of a distal convoluted tubule diuretic. This pairing
would produce augmented natriuresis, and the metabolic acidosis by acetazolamide would be offset by the
metabolic alkalosis of a thiazide or thiazide-like
diuretic.23 In summary, a vicious cycle of sodium surfeit,
vis-a-vis enhanced renal sodium reabsorption may exert
a multiplicative effect through its association with
increased glucocorticoid production, insulin resistance,
and the metabolic syndrome.24
Efforts to mitigate metabolic acidosis in mild-toadvanced CKD by sodium bicarbonate or sodium citrate
have been uniformly successful and associated with
reduced progression of CKD at the level of glomerular
ﬁltration rate and urinary biomarkers. This is particularly
important for CKD patients who cannot abstain from ingesting an acid-rich “red meat” diet, in favor of a vegetable
protein diet. More recently, nutritional alkali therapy, consisting of base-increasing fruits and vegetables, was
compared with placebo and sodium bicarbonate therapy
by Goraya and others.25 Both bicarbonate and fruits and
vegetables were superior to placebo in reduction of urinary angiotensinogen and a decline of the slope of the
glomerular ﬁltration rate over time. Only the fruits and
vegetables group lost weight, and this group had the
lowest end-study blood pressure, despite that all groups
were controlled to a pre-interventional systolic blood pressure of 130 mm Hg. Notably, despite the amount of potassium intrinsic to the fruits and vegetables diet, the
frequency of hyperkalemia did not increase. Congruent
with previous observations of Krishna and associates,
the potassium in the diet likely suppressed the systemic
and intrarenal renin-angiotensin systems and plasma aldosterone, thereby providing a natriuretic effect with a favorable fall in blood pressure.26,27
Taken collectively, sodium still maintains itself as the
nexus of the pathophysiology of hypertension of CKD.
The forces that impinge on sodium retention are complex
but have been increasingly dissected. Several measures to
reduce the high blood pressure of CKD have been clariﬁed and enumerated here, but others remain at the
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exploratory level. Like the Roman god Janus, we have
looked back to sodium as a pathogenic force in the development of hypertension in CKD and must still look forward to it as one, too. Until further notice, “get the salt
out.”
Jerry Yee, MD
Editor-in-Chief
Detroit, MI
Financial Disclosure: The author declares that he has no relevant
ﬁnancial interests.

The critical opinions of a writer should always be
taken with a large grain of salt. For the most part, they are
manifestations of his debate with himself as to what he
should do next and what he should avoid.
—W.H.A.
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